|
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application
Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population.
Key Benefits
Significantly improved protective immunity of vaccine in the aged.
More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 4/23/2024
Contributor(s): Elena Vassilieva, Richard Compans
|
|
Membrane-anchored Fusokine as Vaccine Adjuvant to Prevent Viral Infection
Application
GIFT4 anchored to virus-like particles (VLPs) as a prophylactic vaccine adjuvant to prevent chronic viral infections including HIV, HBV, HPV and influenza.
Key Benefits
GIFT4-containing VLPs induce higher antibody response than non-adjuvanted VLPs.
Effectively induce strong mucosal immune response.
Market Summary
Currently, there...
Published: 4/23/2024
Contributor(s): Baozhong Wang, Richard Compans, Jacques Galipeau, Jiusheng Deng
|
|
Novel Vaccine Antigen Presentation Platforms
Application
Combined antigen-adjuvant virus-like particle (VLP) vaccine platform for enhanced immune response.
Key Benefits
Chimeric VLPs (cVLPs) contain both antigen and adjuvant, thereby enhancing both cellular and humoral responses.
cVLPs are safer than live replicating vectored vaccines because of their lack of infectivity.
The cVLP manufacturing...
Published: 7/28/2023
Contributor(s): Baozhong Wang, Fu Shi Quan, Martin Moore, Richard Compans, Alan Aderem, Ioanna Skountzou, Jadranka Bozja
|
|
Repurposed Kinase Inhibitors as Vaccine Adjuvants
Application
Repurposed, small molecule kinase inhibitors, such as epidermal growth factor receptor (EGFR) inhibitors, as topical vaccine adjuvants.
Key Benefits
Improves immune response and efficacy of vaccines and vaccine candidates.
Employs compounds that are already approved for human use.
Market Summary
In order to create long lasting protection...
Published: 4/23/2024
Contributor(s): Brian Pollack, Richard Compans, Joanna Pulit-Penaloza, Ioanna Skountzou
|
|
HIV Vaccine Using Virus-Like Particles (VLPs)
Application
VLPs containing modified HIV Env have been developed for an AIDS vaccine, capable of inducing cellular and humoral immune responses; including neutralizing activities.
Key Benefits
VLPs are safer than live replicating vectored vaccines because of their lack of infectivity, allowing for use in immunocompromised patients.
HIV VLPs extract...
Published: 4/24/2024
Contributor(s): Richard Compans, Beatrice Hahn, Gale Smith
|